Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for<i>BRAF</i>V600–Mutant Unresectable or Metastatic Melanoma

The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.